Slide 1: Full Year 2025 Performance
FULL YEAR 2025 Performance FULL YEAR & FOURTH QUARTER ENDED 31 DECEMBER 2025 26 February 2026
Slide 2: Note on Forward-Looking Statements
Note on Forward-Looking Statements This presentation may contain certain forward-looking statements including, but not limited to, statements as to future operating results and plans. These statements are based on our assumptions and estimates and are subject to known and unknown risks and uncertain
Slide 3: Performance Review
i sh filet Mier &. 9 hs (iil i ihn "84 ~ « 8
Slide 4: Fourth Quarter 2025 Financial Performance Summary
Performance Review Fourth Quarter 2025 Financial Performance Summary $ Million 4Q 2025 3Q 2025 QoQ % Change 4Q 2024 YoY % Change ▪ Y-o-y comparison: The Group achieved higher revenue of Revenue 113.6 133.5 (14.9) 81.7 39.0 $113.6 million in fourth quarter with EBITDA 17.1 15.6 9.6 13.2 29.5 recurrin
Slide 5: 2H 2025 Financial Performance Summary
Performance Review 2H 2025 Financial Performance Summary $ Million 2H 2025 2H 2024 % Change ▪ The Group delivered a net profit of $24.1 million and revenue of $247.1 million for the Revenue 247.1 248.4 (0.5) second half of the year. EBITDA 32.7 31.4 4.1 ▪ The increase in production activities in Pro
Slide 6: Full Year 2025 Financial Performance Summary
Performance Review Full Year 2025 Financial Performance Summary $ Million FY2025 FY2024 % Change ▪ The Group recorded a lower revenue of $432.5 million and net profit of $40.2 million primarily Revenue 432.5 621.6 (30.4) due to increased competition and lower EBITDA 56.1 91.3 (38.6) customer volume.
Slide 7: Full Year Geographical Revenue
Performance Review Full Year Geographical Revenue FY 2025 Revenue $432.5 million FY 2024 Revenue $621.6 million Others Singapore Others Singapore 1.0% 5.9% 0.4% 5.1% Europe Europe 15.5% 19.3% North America North America 73.8% 79.0%
Slide 8: Free Cash Flow
Performance Review Free Cash Flow ($ Million) FY2025 FY2024 ▪ For the full year ended 31 December 2025, the Group generated: Profit before income tax 47.8 81.1 Operating cash flows before changes -net cash of $38.5 million from its operating 48.0 70.5 in working capital activities; and Cash from ope
Slide 9: Balance Sheet Summary
Performance Review Balance Sheet Summary 31 December 30 June 31 December ▪ Net cash position remained healthy at ($ Million) 2025 2025 2024 $256.4 million as of 31 December 2025. Cash & Bank Balances 123.3 176.3 292.1 Short-term Investments 146.2 51.7 19.2 ▪ Short-term investments comprised Lease Li
Slide 10: Proposed Final & Special Dividends
Proposed Final & Special Dividends
Slide 11: Proposed Final & Special One-Tier Tax-Exempt Cash Dividends
2H 2025 Dividend Proposed Final & Special One-Tier Tax-Exempt Cash Dividends ▪ The Group has maintained a disciplined approach to cash and capital management. As at 31 December 2025, cash reserves stood at $269.5 million and retained profits at $97.1 million. Dividends Payments & Retained Pro fits (
Slide 12: Proposed Final & Special One-Tier Tax-Exempt Cash Dividends
2H 2025 Dividend Proposed Final & Special One-Tier Tax-Exempt Cash Dividends Dividend Per Share (Cents) Net Profit and Dividend Payout 15.0 230.6 ▪ Including the first half interim dividend of 1 cent 100.0 a share, ordinary dividend payout will be 4 12.01 164.1 cents per share for financial year 202
Slide 13: Key Developments
aN / 14am » K vo ments | 7 x. ek: aie ip a A 4 : fi it ils Bre 3, 7 2
Slide 14: Optimisation of Operational Footprint
Key Developments Optimisation of Operational Footprint ▪ Divested Gelang Patah property in Johor, Malaysia and optimised Dongguan manufacturing capacity through sale and partial leaseback1 to improve cost and operational efficiency. ▪ The Group now operates approximately 500,000 sq ft of manufacturi
Slide 15: Enhanced MedTech Manufacturing with FDA Approval
Key Developments Enhanced MedTech Manufacturing with FDA Approval ▪ The ISO 13485 certified manufacturing facility in Pasir Gudang, Johor, Malaysia obtained U.S. Food and Drug Administration (“FDA”) 21 CFR Part 807 Establishment Registration and Device Listing in January 2026. ▪ This significantly s
Slide 16: Project Wins & Customer Expansion
Key Developments Project Wins & Customer Expansion ▪ In financial year 2025, the Group: -secured 27 new project orders1 across a diversified range of high- value technology-driven products (e.g. foetal heart monitor, 3D medical navigation device, AI occupancy sensor, AI-controlled cat flap, smart ai
Slide 17: Customer Diversification Plan
Key Developments Customer Diversification Plan ▪ The Group is leveraging enhanced capabilities and dual-site manufacturing footprint to serve customers in emerging and traditional markets. ▪ Customer Diversification Plan: -To grow presence in the Medtech segment following the U.S. FDA approval for i
Slide 18: Outlook
Aztech " DELIGHTING PEOPLE WITH SMARTER SOLUTIONS.
Slide 19: FY2026 Outlook & Strategic Priorities
Outlook FY2026 Outlook & Strategic Priorities ▪ The business environment remains challenging amidst macroeconomic and geopolitical uncertainties and a softening in customer demand. ▪ To strengthen its position as a trusted and future-ready electronics manufacturing services partner, the Group will f
Slide 20: Thank You
Thank You @& MaNaseD. a DELIGHTING PEOPLE WITH SMARTER SOLUTIONS. SINGAPOREBUSINESSAWARDS